天坛生物：公司“皮下注射人免疫球蛋白”已于2025年6月获得药品GMP符合性检查告知书

Group 1 - The company TianTan Bio (600161.SH) has completed clinical trials for its subcutaneous human immunoglobulin product and plans to submit a marketing authorization application by December 2024 [2] - The product features a protein concentration increased to 20% and utilizes a sugar-free amino acid formulation, transitioning the administration route from intravenous to subcutaneous injection, which offers more effective, comfortable, convenient, and economical treatment options [2] - Upon approval, the product is expected to provide patients with a new treatment choice, enhancing the company's product portfolio [2]